Quest Journals
Journal of Medical and Dental Science Research
Volume 11~ Issue 12 (2024) pp: 86-91
ISSN(Online) : 2394-076X ISSN (Print):2394-0751
www.questjournals.org

Research Paper

Cryoablation Technology:Mechanism, Medical DeviceSystem, Applications, and Future Directions.

Somashekharayya Hiremath
Lead Engineer, Medical Devices, Ablation Technology, United States of America

ABSTRACT: *Cryoablation is a minimally invasive procedure that has emerged as an attractive alternative for treating various diseases by leveraging subzero temperatures rather than heat. Unlike conventional heat-based ablation methods, which destroy tissue by generating intracellular and extracellular ice crystals that often lead to collateral damage, Cryoablation selectively eradicates pathological tissue while preserving surrounding structures. This paper reviews traditional thermal ablation techniques and their inherent challenges, then introduces Cryoablation as a promising solution. This paper focuses on Cryoablation technology, engineering design, and applications. In particular, the design of cryoablation systems (including advanced cryogen delivery and probe configurations) and their integration with imaging modalities are highlighted as critical components for precision medicine. The impact and potential of Cryoablation are discussed in the contexts of oncology, cardiology, gastroenterology, and regenerative medicine. Emerging trends, such as real-time thermal mapping and integration with immunotherapy, underscore the transformative potential of Cryoablation for future healthcare delivery.*
Keywords: *Cryoablation, Ablation Technology, Cryotherapy, Cryogenic Technology, Minimally Invasive, Tissue Ablation, Oncology, Cardiology, Medical Device Engineering.*

I. INTRODUCTION:

Cryoablation employs subzero temperatures to irreversibly damage and eradicate target tissues, offering a minimally invasive alternative to conventional heat-based techniques [1, 2]. Its historical roots extend to the 19th century, but the modern era began in the mid-20th century with the clinical introduction of liquid nitrogen and dedicated cryoprobes [2, 13]. Initially applied in dermatology for superficial lesions, Cryoablation now addresses a wide range of conditions, including cardiac arrhythmias and solid organ tumors—owing to its ability to selectively destroy abnormal cells while preserving critical extracellular matrix structures. This unique feature helps preserve the functionality of organs while minimizing issues, like scarring or loss of function. It reflects the values of precision medicine [1, 4, 10].

Advances in cryogen delivery (using agents such as argon or liquid nitrogen) and cryoprobe engineering have enabled clinicians to precisely target diseased tissue even in complex anatomical regions [10, 15]. Moreover, the integration of imaging modalities (ultrasound, computed tomography [CT], and magnetic resonance imaging (MRI) has improved real-time monitoring of ice ball formation and probe placement, thereby enhancing both safety and efficacy [10, 23, 24]. This paper reviews the technology, engineering aspects, mechanism and future directions of Cryoablation while exploring its applications in oncology, cardiology, gastroenterology, and regenerative medicine.

Main Body:

Conventional heat-based ablation methods, such as microwave ablation, operate by using thermal energy to induce tissue destruction. These methods generate heat that causes coagulative necrosis in target tissues. However, the resulting thermal spread is often difficult to control precisely. As heat dissipates into the surrounding tissues, it may damage adjacent critical structures, leading to unintended scarring, loss of function, and impairment of organ integrity [21, 29]. Treating tumors close to organs or sensitive areas without thermal control can be quite challenging as it can lead to serious complications due to even slight collateral damage inflicted during the process.

Furthermore, patients with substantial comorbidities or those with lesions in complex anatomical sites may be at increased risk from these uncontrolled thermal effects, thereby limiting the applicability of conventional heat-based ablation strategies [3, 18].

Mechanisms of Cryoablation

Cryoablation presents a promising alternative to heat-based modalities by using extreme cold rather than heat to destroy targeted tissue. The fundamental mechanism relies on the rapid freezing of tissue, which induces cell death through several interrelated processes. At the cellular level, rapid cooling results in the formation of intracellular ice crystals that mechanically disrupt cell membranes and intracellular organelles, leading to irreversible cell injury and necrosis [1, 10, 15]. Simultaneously, as the extracellular environment freezes, water is drawn out of cells due to osmotic imbalances; during the subsequent thawing phase, this rapid rehydration causes cellular swelling and eventual rupture of the cell membrane. In addition to these direct cellular effects, the freezing process also inflicts vascular injury by damaging the microvasculature. The formation of ice within small blood vessels causes endothelial disruption and microthrombi formation, further impairing blood flow and oxygen delivery to the tissue, which amplifies the extent of tissue necrosis [1, 11]. There is also emerging evidence that the debris from cryoablated cells can stimulate a local immune response, potentially enhancing tumor clearance by recruiting immune effector cells to the ablation zone [1, 14]. In this way, clinicians can control the growth of the ablation zone using a series of freeze-thaw cycles to gradually encompass the entire lesion with minimal risk to surrounding healthy tissue.



Figure 1: Heat transfer during Cryoablation.

Figure 1: The process of heat transfer in Cryoablation. Cryoablation dynamics are determined by the competition between the heat input rate(Q_{in}), and the heat output rate (Q_{out}),of the region of interest, the ice ball. The size or the diameter (D) of the ice ball is function of the difference between the two transfer rates. At the beginning of Cryoablation, Q_{out} is greater than Q_{in}, and the ice ball keeps on growing larger. However, as it does so, it also increases its surface area, which in turn increases Q_{in} (since more normal temperature tissue is coming into contact with the expanding ice ball). Since Q_{out} is constant and depends only on the flow rate of the expanding gas through the probe, there will come a time when Q_{out}equals Q_{in}($Q_{out} = Q_{in}$), and the ice ball growth will cease. This is the steady-state portion of the Cryoablation, and it is the size of the ice ball at this stage that the manufacturers advertise. The heat transfer rate into the ice ball, Q_{in}, is a function of conductive and convective energy transfers from the surrounding tissues. The former predominates and depends on the surface area of the ice ball, whereas the latter depends on the flow rate of nearby large blood vessels.

Cryoablation Technology and Device

The technical foundation of Cryoablation is rooted in the Joule–Thomson effect, a thermodynamic principle wherein the rapid expansion of a high-pressure gas—typically argon or liquid nitrogen—through a small orifice causes a significant drop in temperature. Liquid nitrogen, with its boiling point of −196°C, is capable of producing deep and extensive ice formations, while argon, although having a higher freezing point around −140°C, is preferred in many modern systems due to its rapid cooling capabilities and ease of integration into automated delivery systems [10, 15]. Modern cryoablation systems are engineered to deliver these cryogens through highly specialized cryoprobes. These probes are typically constructed from biocompatible metals such as stainless steel or titanium, which offer excellent thermal conductivity and mechanical strength, even under extreme cold conditions. The design of the probe incorporates advanced insulation materials to minimize unwanted heat transfer along its shaft, thereby localizing the cooling effect primarily to the probe tip. Additionally, temperature sensors that are commonly in the shape of thermocouples are included within the probe design to offer updates on temperature variations. This information is essential for managing the freeze thaw cycles.



Figure 2: Cryoablation System.

Figure 2: Cryoablation system and its components. The Cryogen (gas) supply during Cryoablation is shown in Figure 2. The Cryogen is stored in a high-pressure cylinder for ultrahigh purity medical gases. The Cryogen gas tanks are connected to the regulator through the high-pressure cables. The regulator is used to begin or end the Cryoablation once the probes are positioned correctly. Infrequently, when the operator wishes to constrain the size of the ice ball, the regulator can reduce the flow rate of Cryogen (gas) to the probe, which in turn reduces the rate of heat removal from the target tissue and, therefore, the final size of the ice ball. The cooling gas is carried to the probe at room temperature and at high pressure through a high-pressure cable. When the gas is released into the two-chambered probe, the pressure equalizes with the ambient pressure at the tip of the probe. When the gas is cooled down below its initial temperature (Joule-Thomson effect), it starts to cool down the probe and surrounding tissues, thus forming the ice ball. The margin of the ice ball corresponds to the 0°C isotherm. The Joule-Thomson effect states that when pressure is quickly reduced, certain gases like nitrogen and argon will cool. The cooled gas then takes energy (Q_{out}) from the tissue in the vicinity of the probe and returns to the regulator.

The cryogenic delivery system is truly impressive in terms of engineering excellence, built to control the flow rate and pressure of the cryogen to reach and sustain temperatures as low as -170°C with precision and accuracy. The mechanisms use automated feedback loops to check data from temperature sensors and make changes to the cryogen flow when it is necessary. One of the most important roles of this precise regulation is to not only increase the efficiency of tissue destruction but also to prevent surrounding tissues from being overcooled. During the Cryogen delivery process, for the procedures success to be guaranteed the incorporation of imaging techniques, like ultrasound, CT and MRI scans is crucial. Real-time imaging allows clinicians to monitor the formation of the ice ball, verify that the ablation zone adequately encompasses the target lesion, and adjust the position of the cryoprobes as needed. This combination of an engineering precision and an advanced imaging is what helps Cryoablation to have high accuracy in the tissue ablation, and thus to reduce risks of the treatment and to create a ground for more tailored and more efficient therapeutic strategies [10, 23, 24].

Applications

Cryoablation has emerged as a transformative treatment modality in modern medicine due to its ability to create highly specific ablation zones with minimal damage to surrounding tissues. This precision makes Cryoablation particularly valuable in treating lesions situated near critical structures where traditional heat-based ablation methods, such as microwave ablation, may pose significant risks of uncontrolled thermal spread, collateral damage, and subsequent functional impairment [21, 29]. The mechanism of cryoablation centers on the controlled application of extreme cold, which enables clinicians to selectively target diseased tissue while preserving the extracellular matrix. This preservation of the structural integrity of healthy tissue not only facilitates improved healing and regeneration but also minimizes post-procedural scarring, a key advantage in the context of precision medicine.

In oncology, Cryoablation is widely used for the treatment of localized tumors in organs, including the kidney, liver, lung, and prostate. For instance, in renal cancer, Cryoablation provides an effective alternative to surgical resection by offering the benefits of lower complication rates and enhanced preservation of renal function. The technical advantage lies in the ability to form well-circumscribed ice balls that can be monitored in real-time via imaging modalities, ensuring that the entire tumor is encompassed within the lethal zone while sparing adjacent healthy parenchyma [3, 4, 17, 26]. Comparative studies have demonstrated that Cryoablation exhibits a favorable safety profile and efficacy that is comparable to other thermal ablation methods, thereby making it particularly suitable for patients who are either poor candidates for surgery or whose tumors are in high-risk anatomical regions [8, 19, 28].

Furthermore, in breast cancer management, Cryoablation is a novel minimally invasive approach that is currently being investigated to potentially decrease the level of surgical intervention required, which could, in turn, enhance cosmetic as well as clinical results [27].

In the realm of gastroenterology, cryotherapy, often delivered through controlled spray techniques, has shown considerable promise in treating precancerous conditions such as Barrett's esophagus and early esophageal cancer. The unique advantage of cryotherapy in this setting is its ability to ablate malignant cells while preserving the underlying extracellular matrix. This preservation is critical for promoting healthier tissue regeneration and for minimizing post-procedural complications such as strictures, which can significantly impact patient quality of life [22]. The ability to perform repeated freeze-thaw cycles further refines the ablation process, enabling tailored treatments that adapt to the specific anatomical and pathological characteristics of each patient.

Cardiology has also embraced Cryoablation, particularly for the treatment of atrial fibrillation. The use of cryoballoon catheters to isolate pulmonary veins by creating transmural lesions has revolutionized the management of cardiac arrhythmias. Cryoablation in this context offers superior control over lesion formation compared to heat based ablation, with the formation of uniform and predictable lesions that reduce the risk of collateral damage to surrounding cardiac tissue. Accurate targeting is achieved with Cryoablation, and leadless cryoprobe systems have been recently developed to improve safety and outcomes of the procedure, thus confirming its prominence in the management of arrhythmias [6,7,14].

In dermatology and regenerative medicine, cryosurgery has a longstanding history in the treatment of superficial skin lesions, including warts, actinic keratoses, and various benign dermatologic conditions. Advances in device technology, such as the development of controlled spray nozzles and integrated temperature feedback systems, have significantly enhanced the precision and reproducibility of cryosurgical interventions. These improvements allow for the effective removal of pathological tissue while minimizing damage to surrounding normal skin, thereby reducing cosmetic complications and promoting rapid healing.

Furthermore, the tissue-sparing aspect of Cryoablation has sparked interest in regenerative medicine, where the preservation of the extracellular matrix is crucial for enabling regulated tissue regeneration and the construction of engineered tissue scaffolds [16]. These clinical applications are illustrative of the more general role that Cryoablation can play as a minimally invasive technique that can provide accurate and controlled tissue destruction with a lower risk of damage to surrounding structures. The use of Cryoablation across multiple specialties, including oncology, gastroenterology, cardiology, and dermatology, underscores the impact of this technology on current healthcare practice. Thus, Cryoablation, which reduces recovery time, lowers complication rates and leads to better patient outcomes, is a prime example of the potential of precision medicine in the 21st century.

Impact on Healthcare Delivery

Cryoablation's minimally invasive nature leads to significantly shorter hospital stays, reduced procedural risks, and faster recovery times, all of which contribute to lowering overall healthcare costs [7, 16]. Because the procedure causes minimal collateral damage, patients experience less postoperative pain and fewer complications, which in turn reduces the need for extended care and decreases the financial burden on healthcare systems. The precise targeting inherent in Cryoablation enables treatment in anatomically challenging regions. This precision allows clinicians to safely ablate lesions that lie close to critical structure areas that are typically considered high risk for conventional surgical methods. As a result, Cryoablation expands therapeutic options for patients who are poor candidates for traditional surgery due to comorbid conditions or the complex location of their tumors [4, 26]. This expanded applicability not only improves individual patient outcomes but also broadens the scope of minimally invasive treatments available to a larger segment of the population.

Furthermore, there is growing evidence that the combination of Cryoablation with systemic therapies, including immunotherapy, may offer better outcomes. Cellular death caused by Cryoablation can lead to the presentation of tumor antigens and may help to activate the immune system to kill residual cancer cells. This synergistic approach seems to improve the overall oncologic efficacy and recurrence rates and thus open the way for more integrated, multimodal cancer treatment strategies [14, 27]. In this manner, Cryoablation is not only changing the immediate clinical practice but is also defining the future of interventional and precision medicine.

Future Directions and Emerging Trends

The ongoing progress of cryotherapy technology is projected to improve its accuracy and safety while expanding its use in medical specialties.One key area of innovation is the miniaturization and increased flexibility of cryoprobes, which will allow for more precise targeting of deep-seated or anatomically challenging lesions. The development of thinner, more maneuverable probes will enable Cryoablation to be performed in delicate and complex regions where conventional thermal ablation techniques may pose risks of collateral damage. This advancement will make it easier to introduce cryotherapy into fields, like endoscopy and invasive procedures. This will lead to improved results for patients. Increase the availability of treatment options [10, 15].

Another major advancement in Cryoablation is the emergence of portable Cryoablation systems, which could extend access to treatment in remote or resource-limited settings. Currently, Cryoablation requires large stationary equipment that restricts its application to specialized medical centers. Thus, by creating small and transportable cryoablation units, doctors can provide very exact and non-invasive therapy to patients as outpatient, or in rural or emergency settings hospitals. This could help improve patient care through better use of limited resources in underserved areas, while also helping to lower the overall costs of procedures that now take place in hospitals [16].The integration of real-time thermal mapping with cryoablation systems is also poised to revolutionize the field. The current state-of-the-art imaging and temperature sensing software is being created to pivot freezing parameters in real-time based on feedback. These systems will continue to track the ice ball formation with imaging modalities like ultrasound, CT, and MRI to ensure continuous monitoring of the process and, hence, complete tumor ablation with minimal risk to surrounding tissues. This technological advancement will improve the accuracy of the procedure, lead to more uniform treatment results, and increase the safety of the procedure, especially when tumors near vital structures are treated [10, 24].

Another emerging trend in cryoablation research is its integration with immunotherapy. Cryoablation has demonstrated the ability to trigger a response by releasing tumor antigens when destroying cells in the body. This impact on the system implies that cryotherapy could play a part in improving overall cancer treatment when combined with checkpoint inhibitors, optimal cell therapies, and cancer vaccines to better manage tumors throughout the body.Ongoing research is exploring the extent to which cryoablation-induced antigen release can prime the immune system to recognize and attack metastatic cancer cells. By combining Cryoablation with immunotherapeutic agents, researchers aim to develop more effective and durable cancer treatments, particularly for patients with advanced or recurrent malignancies [14, 27].

Finally, automation and artificial intelligence (AI) are anticipated to significantly enhance the precision and efficiency of cryoablation procedures. The integration of AI-driven algorithms with robotics could facilitate automated cryoprobe placement, optimize cryogen delivery, and provide real-time adjustments based on intraoperative imaging and thermal data. AI-based systems have the potential to reduce operator dependency, minimize procedural variability, and standardize cryoablation techniques across different clinical settings. This technological evolution could also accelerate the adoption of Cryoablation in routine clinical practice by simplifying the procedure and reducing the need for highly specialized training [20, 21].

As technology progresses further in the medical field, cryotherapy treatment is set to become more prevalent in precision medicine settings. The combination of tools, equipment, live imaging immunotherapy inclusion, and automation powered by artificial intelligence will propel the advancement of cryotherapy technologies in the future. These new Cryoablation developments will not only improve outcomes and reduce procedure time but also increase the number of diseases that can be treated with cryotherapy, thus defining it as a cornerstone of modern interventional medicine.

II. CONCLUSION:

Cryoablation has seen advancements and has become a key part of minimally invasive treatments across various medical fields by using subzero temperatures to ablate or cause damage to tissue, tumors, cells, and vessels. Cryotherapy offers benefits not found in heat-based ablation methods. Progress in delivering cryogens, designing probes, and combining them with imaging technologies has allowed targeting tissue while protecting nearby vital structures. Cryoablation is poised to become even more integral to personalized, precision medicine as innovations continue, particularly in real-time thermal mapping, probe miniaturization, and AI-driven procedural control. Its expanding role in oncology, cardiology, gastroenterology, and regenerative medicine underscores its transformative potential in modern healthcare delivery.

REFERENCES:

[1] Gage, A. A., & Baust, J. (1998). Mechanisms of tissue injury in cryosurgery. Cryobiology, 37(3), 171–186. https://doi.org/10.1006/cryo.1998.2115

[2] COOPER, I. S., & LEE, A. S. (1961). Cryostatic congelation: a system for producing a limited, controlled region of cooling or freezing of biologic tissues. The Journal of nervous and mental disease, 133, 259–263.

[3] Bisbee II, Charles A., Jeremy Zhang, Justin Owens, Syed Hussain, and Justin L. Owens. "Cryoablation for the treatment of kidney cancer: comparison with other treatment modalities and review of current treatment." Cureus 14, no. 11 (2022).
[4] Autorino, R., &Kaouk, J. H. (2012, July). Cryoablation for small renal tumors: current status and future perspectives. In Urologic Oncology: Seminars and Original Investigations (Vol. 30, No. 4, pp. S20-S27). Elsevier.
[5] Hammer, D., Büdi, L., Nagy, Á., Varga, R., & Horváth, P. (2023). Evaluation of a transbronchial cryoprobe for the ablation of pulmonary nodules: an in vitro pilot study. BMC pulmonary medicine, 23(1), 71.
[6] Farkowski, M. M., Karlinski, M., Barra, S., Providencia, R., Golicki, D., Pytkowski, M., ... &Boveda, S. (2022). Effectiveness and safety of a single freeze strategy of cryoballoon ablation of atrial fibrillation: an EHRA systematic review and meta-analysis. EP Europace, 24(1), 58-69.
[7] Abdin, A., Yalin, K., Lyan, E., Sawan, N., Liosis, S., Meyer-Saraei, R., ... &Tilz, R. R. (2019). Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in elderly patients. Clinical Research in Cardiology, 108, 167-174.
[8] Schmit, G. D., Atwell, T. D., Leibovich, B. C., Callstrom, M. R., Kurup, A. N., Woodrum, D. A., & Charboneau, J. W. (2010). Percutaneous cryoablation of anterior renal masses: technique, efficacy, and safety. American Journal of Roentgenology, 195(6), 1418-1422.
[9] Eiken, P. W., & Welch, B. T. (2019, October). Cryoablation of lung metastases: review of recent literature and ablation technique. In Seminars in Interventional Radiology (Vol. 36, No. 04, pp. 319-325). Thieme Medical Publishers.
[10] Erinjeri, J. P., & Clark, T. W. (2010). Cryoablation: mechanism of action and devices. Journal of vascular and interventional radiology : JVIR, 21(8 Suppl), S187–S191. https://doi.org/10.1016/j.jvir.2009.12.403.
[11] Gage, A. A., Baust, J. M., & Baust, J. G. (2009). Experimental cryosurgery investigations in vivo. Cryobiology, 59(3), 229–243. https://doi.org/10.1016/j.cryobiol.2009.10.001
[12] Chang, D., Mohan, P., Amin, A., Garcia-Buitrago, M., Rodriguez, J., &Peaden, R. (2020). Liquid Nitrogen-Based Cryoablation in In Vivo Porcine Tissue: A Pilot Study. Asian Pacific journal of cancer prevention : APJCP, 21(10), 3069–3075. https://doi.org/10.31557/APJCP.2020.21.10.3069
[13] Pasquali, P. (2015). Cryosurgery: A practical manual. Springer. https://doi.org/10.1007/978-3-662-43939-5.
[14] Baust, J. M., et al. (2018). Evaluation of a new epicardial cryoablation system for the treatment of cardiac tachyarrhythmias. SAGE Open Medicine, 6, 2050312118769797. https://doi.org/10.1177/2050312118769797 .
[15] Hewitt, P. M., Zhao, J., Akhter, J., & Morris, D. L. (1997). A comparative laboratory study of liquid nitrogen and argon gas cryosurgery systems. Cryobiology, 35(4), 303–308. https://doi.org/10.1006/cryo.1997.2039
[16] Alzubaidi, S. J., Liou, H., Saini, G., Segaran, N., Scott Kriegshauser, J., Naidu, S. G., ... &Oklu, R. (2021). Percutaneous image-guided ablation of lung tumors. Journal of Clinical Medicine, 10(24), 5783.
[17] Aron, M., Kamoi, K., Remer, E., Berger, A., Desai, M., & Gill, I. (2010). Laparoscopic renal cryoablation: 8-year, single surgeon outcomes. The Journal of urology, 183(3), 889–895. https://doi.org/10.1016/j.juro.2009.11.041
[18] Atwell, T. D., Carter, R. E., Schmit, G. D., Carr, C. M., Boorjian, S. A., Curry, T. B., Thompson, R. H., Kurup, A. N., Weisbrod, A. J., Chow, G. K., Leibovich, B. C., Callstrom, M. R., & Patterson, D. E. (2012). Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. Journal of vascular and interventional radiology : JVIR, 23(1), 48–54. https://doi.org/10.1016/j.jvir.2011.09.008.
[19] El Dib, R., Touma, N. J., &Kapoor, A. (2012). Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU international, 110(4), 510–516. https://doi.org/10.1111/j.1464-410X.2011.10885.x
[20] Guillotreau, J., Haber, G. P., Autorino, R., Miocinovic, R., Hillyer, S., Hernandez, A., Laydner, H., Yakoubi, R., Isac, W., Long, J. A., Stein, R. J., &Kaouk, J. H. (2012). Robotic partial nephrectomy versus laparoscopic cryoablation for the small renal mass. European urology, 61(5), 899–904. https://doi.org/10.1016/j.eururo.2012.01.007
[21] Hinshaw, J. L., Lubner, M. G., Ziemlewicz, T. J., Lee, F. T., Jr, & Brace, C. L. (2014). Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation--what should you use and why?. Radiographics : a review publication of the Radiological Society of North America, Inc, 34(5), 1344–1362. https://doi.org/10.1148/rg.345140054
[22] Hutchinson, M.J., Shyn, P.B., Silverman, S.G. (2013). Cryoablation of Liver Tumors. In: Dupuy, D., Fong, Y., McMullen, W. (eds) Image-Guided Cancer Therapy. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0751-6_35
[23] Lee, S. M., Won, J. Y., Lee, D. Y., Lee, K. H., Lee, K. S., Paik, Y. H., & Kim, J. K. (2011). Percutaneous cryoablation of small hepatocellular carcinomas using a 17-gauge ultrathin probe. Clinicalradiology, 66(8), 752–759. https://doi.org/10.1016/j.crad.2011.02.015
[24] Littrup, P. J., Jallad, B., Vorugu, V., Littrup, G., Currier, B., George, M., & Herring, D. (2009). Lethal isotherms of cryoablation in a phantom study: effects of heat load, probe size, and number. Journal of vascular and interventional radiology : JVIR, 20(10), 1343–1351. https://doi.org/10.1016/j.jvir.2009.05.038
[25] **National Institute for Health and Care Excellence (NICE).** (2012). Focal therapy using cryoablation for localised prostate cancer (Interventional procedures guidance [IPG423]). https://www.nice.org.uk/guidance/ipg423/chapter/2-The-procedure
[26] Pessoa, R. R., Autorino, R., Laguna, M. P., Molina, W. R., Gustafson, D., Nogueira, L., da Silva, R. D., Werahera, P. N., & Kim, F. J. (2017). Laparoscopic Versus Percutaneous Cryoablation of Small Renal Mass: Systematic Review and Cumulative Analysis of Comparative Studies. Clinical genitourinary cancer, 15(5), 513–519.e5. https://doi.org/10.1016/j.clgc.2017.02.003
[27] Simmons, R. M., Ballman, K. V., Cox, C., Carp, N., Sabol, J., Hwang, R. F., Attai, D., Sabel, M., Nathanson, D., Kenler, A., Gold, L., Kaufman, C., Han, L., Bleznak, A., Stanley Smith, J., Holmes, D., Fornage, B., Le-Petross, C., Hoda, S., McCall, L., … ACOSOG investigators (2016). A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. Annals of surgical oncology, 23(8), 2438–2445. https://doi.org/10.1245/s10434-016-5275-3
[28] Wang, C., Wang, H., Yang, W., Hu, K., Xie, H., Hu, K. Q., Bai, W., Dong, Z., Lu, Y., Zeng, Z., Lou, M., Wang, H., Gao, X., Chang, X., An, L., Qu, J., Li, J., & Yang, Y. (2015). Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology (Baltimore, Md.), 61(5), 1579–1590. https://doi.org/10.1002/hep.27548.
[29] Weber, S. M., & Lee, F. T., Jr (2005). Expanded treatment of hepatic tumors with radiofrequency ablation and cryoablation. Oncology (Williston Park, N.Y.), 19(11 Suppl 4), 27–32.
[30] Yang, Y., Wang, C., Lu, Y., Bai, W., An, L., Qu, J., Gao, X., Chen, Y., Zhou, L., Wu, Y., Feng, Y., Zhang, M., Chang, X., & Lv, J. (2012). Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. Journal of hepato-biliary-pancreatic sciences, 19(6), 674–684. https://doi.org/10.1007/s00534-011-0490-6
[31] Mazaris, E. M., Varkarakis, I. M., & Solomon, S. B. (2008). Percutaneous renal cryoablation: current status. Future oncology, 4(2), 257-269.